Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Indivior PLC
Indivior PLC
Activities:
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Design & Build
Indivior awards BES £4m design project
The cleanroom construction company has been chosen to create a new production facility for the opioid addiction treatment specialist
Design & Build
Boulting Environmental Services completes Indivior R&D facility
The UK-based cleanroom and lab design and construction company has completed the construction phase of a £13 million project for global pharmaceutical business Indivior, a specialist in the treatment of opioid addiction
Research & Development
New schizophrenia drug may improve patient compliance
RBP-7000, new pipeline novel sustained-release drug by Indivior, showed patients “stable or improved” throughout test period
Subscribe now